MedTrace Logo

sCD163 as a Potential Biomarker in Guillain- Barré Syndrome

NCT02582853 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2015-10-22

No results posted yet for this study

Summary

Guillain- Barré syndrome (GBS) is an acute inflammatory demyelinating polyneuropathy (AIDP) that often is triggered by an infection. GBS is characterized by progressing weakness and numbness and loss of tendon of reflexes. It can also include tingling sensation in the legs and arms. These symptoms occur due to an autoimmune attack on the myelin resulting in demyelination.

The diagnosis is given by electrophysiological examination and clinical presentation.

GBS is treated with intravenous immunoglobulin (IVIG) and plasma exchange (PE). Both treatments are equally effective. Most patients recover completely, while others must ease symptoms and reduce the duration of illness by several treatments.

The purpose of this study is to define if patients with GBS have higher concentrations of sCD163 in their cerebrospinal fluid and serum compared with symptomatic control subjects. Furthermore it is to define if the concentrations of sCD163 reduces after treatment.

Conditions

  • Guillain-Barre Syndrome

Interventions

PROCEDURE

Lumbar puncture

Lumbar puncture for spinal fluid

PROCEDURE

Blood Sample

Blood sample

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Henning Andersen, Professor · Department of Neurology

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-11-30
Completion
2018-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02582853 on ClinicalTrials.gov